MBX Biosciences (MBX) EBT (2023 - 2026)
MBX Biosciences (MBX) posted EBT of -$102.0 million for Q1 2026, down 584.29% sequentially from -$14.9 million in Q4 2025, and down 277.35% YoY from $57.5 million in Q1 2025.
MBX Biosciences (MBX) EBT (2023 - 2026) Analysis & Trends
MBX Biosciences has reported EBT for 4 years, with the latest figure at -$102.0 million in Q1 2026.
- Quarterly EBT fell 277.35% year-over-year to -$102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$213.7 million (down 181.93% YoY) and the FY2025 annual result came in at -$184.7 million, down 78.69% from the prior year.
- EBT slipped to -$102.0 million in Q1 2026 per MBX's latest filing, from -$14.9 million in the prior quarter.
- Over five years, EBT peaked at -$10.9 million in Q3 2023 and troughed at -$102.0 million in Q1 2026.
- A 4-year average of -$29.8 million and a median of -$16.8 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2026: EBT gained 13.78% in 2024, then tumbled 277.35% in 2026.
- Over 4 years, EBT stood at -$14.5 million in 2023, then grew by 13.78% to -$12.5 million in 2024, then decreased by 19.43% to -$14.9 million in 2025, then slumped by 584.29% to -$102.0 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$102.0 million, -$14.9 million, and -$61.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | -223.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -223.79 Mn |
| Mar 31, 2026 | -102.03 Mn |
| Dec 31, 2025 | -14.91 Mn |
| Sep 30, 2025 | -61.94 Mn |
| Jun 30, 2025 | -34.78 Mn |
| Mar 31, 2025 | -27.04 Mn |
| Dec 31, 2024 | -12.48 Mn |
| Sep 30, 2024 | -19.49 Mn |
| Jun 30, 2024 | -16.77 Mn |
| Mar 31, 2024 | -13.48 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -10.94 Mn |